CinCor is a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, CIN-107, a highly selective, oral small molecule inhibitor of aldosterone synthase, for the treatment of hypertension and other cardio-renal diseases.
*Assuming exercise of underwriter’s option.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”